Prime Medicine, Inc.
PRME
$0.23
Change (1 day)
$9.86
Year High
$2.85
Year Low
Categories
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
P/B ratio for Prime Medicine, Inc. (PRME)
P/B ratio as of 2023: 6.06
According to Prime Medicine, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.06. At the end of 2022 the company had a P/B ratio of -6.15.
P/B ratio history for Prime Medicine, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 6.06 |
| 2022 | -6.15 |
| 2021 | 4.16 |
| 2020 | 32.97 |
| 2019 | 1059.30 |